JP2021501897A - Gcc2遺伝子又はタンパク質を過発現するエクソソーム基盤肺癌診断又は予後予測用マーカー組成物 - Google Patents
Gcc2遺伝子又はタンパク質を過発現するエクソソーム基盤肺癌診断又は予後予測用マーカー組成物 Download PDFInfo
- Publication number
- JP2021501897A JP2021501897A JP2020524788A JP2020524788A JP2021501897A JP 2021501897 A JP2021501897 A JP 2021501897A JP 2020524788 A JP2020524788 A JP 2020524788A JP 2020524788 A JP2020524788 A JP 2020524788A JP 2021501897 A JP2021501897 A JP 2021501897A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- lung cancer
- gcc2
- exosome
- prognosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
したがって、非侵襲性、高感度、及び高特異性における癌の早期診断法の開発が求められている実状であるが、現在まで、癌の診断において早期に特異的に病巣を検知し、発病可否を判断する分子的な診断技術はほとんどなく、さらに、特定の癌に特異的に適用される方法は存在しない状況である。
5種の肺癌細胞株(H522、A549、H1650、PC9、H1299)をそれぞれ直径150mmのディッシュで培養した。ここで、超高速遠心分離機を用いて120、000gで4時間の間に遠心分離し、エクソソームを除去したFBS(Fetal Bovine Serum)の上層液を培養液として使用した。前記培養液を用いて、細胞が70−80%confluency状態になるよう2−3日間連続培養した。
前記実施形態1により選別したGCC2遺伝子の細胞内の発現水準を確認するため、定量的な逆転写重合酵素連鎖反応(qRT−PCR)を行った。
GCC2は、エクソソームの生成に関わっているものと推定されるタンパク質であるため、正常細胞株(HPAECs)と肺癌細胞株(H1299、H522)におけるエクソソームの分泌量を測定した。エクソソームの分泌量は、DLS(Dynamic Light Scattering)を用いて間接的に測定した。
前記実施形態1により収得したエクソソーム内のGCC2タンパク質の発現水準を確認するため、ウェスタンブロッティングを実施した。
GCC2タンパク質を含むエクソソームが肺癌診断又は予後予測用マーカーとして利用可能であるか否かを確認するため、下記のような試験を行った。
Claims (8)
- GCC2(GRIP and coiled−coil domain−containing protein)タンパク質の過発現エクソソームを含む、肺癌診断又は予後予測用マーカー組成物。
- エクソソーム(exosome)内のGCC2(GRIP and coiled−coil domain−containing protein)遺伝子に特異的に結合するプライマー又はプローブを含む、肺癌診断又は予後予測用組成物。
- エクソソーム(exosome)内のGCC2(GRIP and coiled−coil domain−containing protein)タンパク質に特異的に結合する抗体を含む、肺癌診断又は予後予測用組成物。
- 請求項2又は請求項3の組成物を含む、肺癌診断又は予後予測用キット。
- 前記キットは、RT−PCRキット、マイクロアレイチップキット、DNAキット、及びタンパク質チップキットからなる群から選択される1つ以上である、請求項4に記載の肺癌診断又は予後予測用キット。
- (a)生物学的試料からエクソソーム(exosome)を分離するステップと、
(b)前記エクソソーム内のGCC2(GRIP and coiled−coil domain−containing protein)遺伝子又はタンパク質の発現水準を測定するステップとを含む、肺癌診断又は予後の予測に必要な情報を提供する方法。 - 前記生物学的試料は、全血、血清、血漿、唾液、尿、喀痰、リンパ液、及び細胞からなる群から選択される1つ以上である、請求項6に記載の肺癌診断又は予後の予測に必要な情報を提供する方法。
- (a)肺癌患者から採取した生物学的試料に肺癌治療剤候補物質を処理するステップと、
(b)前記生物学的試料からエクソソーム(exosome)を分離するステップと、
(c)前記エクソソーム内のGCC2(GRIP and coiled−coil domain−containing protein)遺伝子又はタンパク質の発現水準を測定するステップとを含む、肺癌治療剤のスクリーニング方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0147510 | 2017-11-07 | ||
KR1020170147510A KR102080887B1 (ko) | 2017-11-07 | 2017-11-07 | Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물 |
PCT/KR2018/013220 WO2019093717A2 (ko) | 2017-11-07 | 2018-11-02 | Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021501897A true JP2021501897A (ja) | 2021-01-21 |
JP6908785B2 JP6908785B2 (ja) | 2021-07-28 |
Family
ID=66438917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020524788A Active JP6908785B2 (ja) | 2017-11-07 | 2018-11-02 | Gcc2遺伝子又はタンパク質を過発現するエクソソーム基盤肺癌診断又は予後予測用マーカー組成物 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20210018505A1 (ja) |
JP (1) | JP6908785B2 (ja) |
KR (1) | KR102080887B1 (ja) |
CN (1) | CN111373056A (ja) |
WO (1) | WO2019093717A2 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113785200A (zh) | 2019-04-03 | 2021-12-10 | 高丽大学校产学协力团 | 基于过表达tuba1c蛋白的外泌体的诊断癌症或预测预后的标志物组合物 |
KR102318328B1 (ko) * | 2020-04-13 | 2021-10-27 | 고려대학교 산학협력단 | Gcc2 단백질을 과발현하는 엑소좀 기반 암 진단 또는 예후 예측용 마커 조성물 |
KR20230084704A (ko) | 2021-12-06 | 2023-06-13 | 주식회사 엑소퍼트 | Gcc2 억제제를 유효성분으로 포함하는 폐암 예방 또는 치료용 조성물 |
KR20240017323A (ko) | 2022-07-29 | 2024-02-07 | 고려대학교 산학협력단 | Gcc2 발현 억제제를 유효성분으로 포함하는 폐암 예방또는 치료용 약학적 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007026896A1 (ja) * | 2005-09-02 | 2007-03-08 | Toray Industries, Inc. | 腎ガン診断、腎ガン患者予後予測のための組成物および方法 |
WO2010115077A2 (en) * | 2009-04-02 | 2010-10-07 | The Johns Hopkins University | Biomarker panels for barrett's esophagus and esophageal adenocarcinoma |
JP2015516985A (ja) * | 2012-04-27 | 2015-06-18 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 抗gcc抗体分子、およびgcc標的化療法への感受性を試験するためのその使用 |
WO2017181183A1 (en) * | 2016-04-15 | 2017-10-19 | Exosome Diagnostics, Inc. | Plasma-based detection of anaplastic lymphoma kinase (alk) nucleic acids and alk fusion transcripts and uses thereof in diagnosis and treatment of cancer |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100690250B1 (ko) | 2005-01-31 | 2007-03-12 | 디지탈 지노믹스(주) | 폐암 진단용 마커 |
US7871774B2 (en) | 2005-01-31 | 2011-01-18 | Digital Genomics Inc. | Markers for the diagnosis of lung cancer |
EP3115469B1 (en) | 2007-11-19 | 2020-04-29 | Celera Corporation | Lung cancer markers and uses thereof |
WO2009085237A2 (en) * | 2007-12-21 | 2009-07-09 | Cell Genesys, Inc. | Methods and compositions for identifying lung cancer or a humoral immune response against lung cancer |
US20120058492A1 (en) * | 2008-01-25 | 2012-03-08 | Hansabiomed Ou | Method and a Kit To Detect Malignant Tumors and Provide a Prognosis |
EP3181705A1 (en) * | 2008-11-12 | 2017-06-21 | Caris Life Sciences Switzerland Holdings GmbH | Methods and systems of using exosomes for determining phenotypes |
EP2430189B1 (en) * | 2009-05-12 | 2018-11-21 | Koninklijke Philips N.V. | Phosphodiesterase 9a as prostate cancer marker |
DK2430191T3 (en) * | 2009-05-12 | 2018-12-10 | Koninklijke Philips Nv | PHOSPHODIESTERASE-4D7 AS A MARKET FOR PROSTATACANCES |
KR101371127B1 (ko) | 2010-11-23 | 2014-03-10 | 한양대학교 산학협력단 | Her2와 결합하는 krt19 및 그 용도 |
WO2012135844A2 (en) * | 2011-04-01 | 2012-10-04 | Cornell University | Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers |
KR101680360B1 (ko) | 2014-01-22 | 2016-11-28 | 주식회사 엑쏘좀 | Del-1 단백질 양성 엑소좀을 포함하는 암 진단 또는 예후 예측용 조성물 |
KR20160133740A (ko) * | 2015-05-13 | 2016-11-23 | 경북대학교 산학협력단 | 파이브로넥틴 단백질 양성 엑소좀을 포함하는 암 진단 또는 예후 예측용 조성물 |
-
2017
- 2017-11-07 KR KR1020170147510A patent/KR102080887B1/ko active IP Right Grant
-
2018
- 2018-11-02 JP JP2020524788A patent/JP6908785B2/ja active Active
- 2018-11-02 US US16/762,140 patent/US20210018505A1/en not_active Abandoned
- 2018-11-02 CN CN201880072074.2A patent/CN111373056A/zh active Pending
- 2018-11-02 WO PCT/KR2018/013220 patent/WO2019093717A2/ko active Application Filing
-
2021
- 2021-11-30 US US17/539,030 patent/US12000832B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007026896A1 (ja) * | 2005-09-02 | 2007-03-08 | Toray Industries, Inc. | 腎ガン診断、腎ガン患者予後予測のための組成物および方法 |
WO2010115077A2 (en) * | 2009-04-02 | 2010-10-07 | The Johns Hopkins University | Biomarker panels for barrett's esophagus and esophageal adenocarcinoma |
JP2015516985A (ja) * | 2012-04-27 | 2015-06-18 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 抗gcc抗体分子、およびgcc標的化療法への感受性を試験するためのその使用 |
WO2017181183A1 (en) * | 2016-04-15 | 2017-10-19 | Exosome Diagnostics, Inc. | Plasma-based detection of anaplastic lymphoma kinase (alk) nucleic acids and alk fusion transcripts and uses thereof in diagnosis and treatment of cancer |
Non-Patent Citations (4)
Title |
---|
JIANG, J. ET AL.: "GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK in", LUNG CANCER, vol. 115, JPN6021005901, 2018, pages 5 - 11, ISSN: 0004450743 * |
NOH, K. W. ET AL.: "Molecular breakdown: a comprehensive view of anaplasticlymphoma kinase (ALK)-rearranged non-small ce", JOURNAL OF PATHOLOGY, vol. 243, JPN6021005905, 28 September 2017 (2017-09-28), pages 307 - 319, ISSN: 0004450744 * |
NOH, K. W. ET AL.: "The Molecular Breakdown: A Comprehensive Look at Non-Small-Cell Lung Cancer with ALK Rearrangement", JOURNAL OF THORACIC ONCOLOGY, vol. Vol.12, No.1S, JPN6021005906, 1 January 2017 (2017-01-01), pages 500 - 501, ISSN: 0004450745 * |
VENDRELL, J. A. ET AL.: "Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation se", SCIENTIFIC REPORTS, vol. 7, no. 12510, JPN6021005898, 2 October 2017 (2017-10-02), pages 1 - 11, ISSN: 0004450742 * |
Also Published As
Publication number | Publication date |
---|---|
KR102080887B1 (ko) | 2020-02-24 |
US20220196664A1 (en) | 2022-06-23 |
US12000832B2 (en) | 2024-06-04 |
US20210018505A1 (en) | 2021-01-21 |
WO2019093717A3 (ko) | 2019-06-27 |
CN111373056A (zh) | 2020-07-03 |
JP6908785B2 (ja) | 2021-07-28 |
KR20190051641A (ko) | 2019-05-15 |
WO2019093717A2 (ko) | 2019-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6908785B2 (ja) | Gcc2遺伝子又はタンパク質を過発現するエクソソーム基盤肺癌診断又は予後予測用マーカー組成物 | |
He et al. | HLA-G expression in human breast cancer: implications for diagnosis and prognosis, and effect on allocytotoxic lymphocyte response after hormone treatment in vitro | |
Tokuishi et al. | Splice variant HE4-V3 expression is associated with favorable prognosis in pulmonary adenocarcinoma | |
Shin et al. | Identification of ganglioside GM 2 activator playing a role in cancer cell migration through proteomic analysis of breast cancer secretomes | |
Wang et al. | Long non-coding RNA AK093407 promotes proliferation and inhibits apoptosis of human osteosarcoma cells via STAT3 activation | |
JP2022130598A (ja) | 血液から癌を診断する方法 | |
US20210116459A1 (en) | Biomarkers and uses thereof | |
JP6192122B2 (ja) | 結腸直腸癌診断および予測のためのバイオマーカー | |
US20150338412A1 (en) | Composition for diagnosis of lung cancer and diagnosis kit for lung cancer | |
KR102328932B1 (ko) | 신장이식 후 항체 매개성 거부반응의 진단 또는 예측을 위한 소변 엑소좀 바이오마커 | |
KR101995189B1 (ko) | 비침습적 체외진단을 위한 간암 진단용 바이오마커 조성물 및 이를 포함하는 키트 | |
US11408886B2 (en) | Method of screening for novel therapeutic targets to develop therapeutic agents for colon cancer and prognostic biomarkers for colon cancer treatment screened using the same | |
US20140248637A1 (en) | Composition for diagnosis of lung cancer and diagnosis kit of lung cancer | |
CN111289749B (zh) | C型1类尼曼-匹克蛋白检测物在制备筛查肝细胞癌产品中的应用 | |
JP7222117B2 (ja) | Tuba1cタンパク質を過発現するエクソソーム基盤の癌の診断又は予後予測用マーカー組成物 | |
KR102350603B1 (ko) | Tuba1c 단백질을 과발현하는 엑소좀 기반 암 진단 또는 예후 예측용 마커 조성물 | |
JP2021019612A (ja) | 治療剤に対する抵抗性の診断に使用するためのERCC1アイソフォーム3のmRNAおよび/またはタンパク質ならびにこのmRNAおよび/またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 | |
JP6691337B2 (ja) | 膀胱癌患者の予後を予測するための方法 | |
EP2772759A1 (en) | Composition for diagnosis of lung cancer | |
KR102318328B1 (ko) | Gcc2 단백질을 과발현하는 엑소좀 기반 암 진단 또는 예후 예측용 마커 조성물 | |
US20230045066A1 (en) | Biomarkers for diagnosing breast cancer and uses thereof | |
US20220334119A1 (en) | Protein panels for the early diagnosis/prognosis and treatment of aggressive prostate cancer | |
KR20230020820A (ko) | 유방암 진단용 바이오마커 및 이의 용도 | |
CN117778558A (zh) | Igfbp3基因在制备筛查宫腔粘连的相关产品的应用 | |
SCULLY | ROLE OF COMPLEMENT COMPONENT 1, Q SUBCOMPONENT BINDING PROTEIN (C1QBP) IN BREAST CARCINOGENESIS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200507 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210301 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210527 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210607 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210701 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6908785 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |